Patients with intermediate-high risk MGUS are not offered therapeutic options to date and standard of care remains observation with re-evaluations of the patient every 3 to 6 months. Given the persistent risk of progression as well as potential complications experienced by some, and anxiety experienced by most patients, early intervention with non-toxic curcumin, aimed at potentially slowing down or stopping disease progression might be therapeutic. We present here an intermediate-high risk MGUS patient who has been taking curcumin for 16 years and has shown a decrease in disease markers and an increase in uninvolved immunoglobulins, adding to the body of evidence of benefit of curcumin to MGUS patients.
Researchers in a new study found that obesity, smoking habits and exercise may impact one s likelihood of developing a benign blood condition that often precedes multiple myeloma (a blood cancer of the plasma cells).
The X-linked syndrome is a systemic autoinflammatory disease of undefined origin. It resists the classic therapeutic arsenal, but Janus kinase pathway inhibitors show promise as treatments.